Figure GPS-18. Overview of drug prevalence estimates in Europe for all adults (aged 15–64) and young adults (aged 15–34)

Part (ii) Cocaine, amphetamines and ecstasy use: lifetime experience, last 12 months and last 30 days prevalence

Substance	Belgium	Bulgaria	Czech Republic	Denmark	Germany	Estonia	Ireland	Greece	Spain	France	Italy	Cyprus	Latvia	Lithuania	Hungary	Malta	Netherlands	Austria	Poland	Portugal	Romania	Slovakia	Finland	Sweden	UK (England and Wales)	Croatia	Turkey	Norway	EU average
Cocaine LTP All adults		1.7	1.4	4.4	3.3		6.8	0.7	8.8	3.7	4.2	3.0	1.5	0.5	0.9	0.4	5.2	2.2	1.3	1.9	0.3	0.6	1.7	3.3	9.6	2.3		2.5	4.2
Cocaine LYP All adults	0.9	0.7	0.6	0.9	0.8	0.7	1.5	0.1	2.3	0.9	0.6	1.2	0.2	0.2	0.2	0.3	1.2	0.9	0.7	0.6	0.1	0.2	0.2	0.5	2.2	0.5		0.4	1
Cocaine LMP All adults		0.4	0.1	0.2	0.3	0.1	0.5	0	1.1		0.2	0.7	0.1	0.1	0.2	0.1	0.5	0.6	0.5	0.3	0	0.1	0	0.1	1	0.3		0.2	0.5
Amphetamines LTP All adults		2.1	2.1	6.2	3.7		4.5	0.1	3.3	1.7	1.8	0.7	2.2	1.6	1.8	0.4	3.1	2.5	4.2	0.9	0.1	0.5	2.3	5	11.5	2.6	0.3	3.8	3.7
Amphetamines LYP All adults		0.9	0.8	0.7	0.7	1.1	0.4	0	0.6	0.2	0.1	0.3	0.3	0.7	0.5	0	0.4	0.5	1.9	0.2	0	0.1	0.8	0.8	0.8	0.8		0.7	0.6
Amphetamines LMP All adults		0.5	0	0.3	0.3	0.5	0.1	0	0.3		0	0.2	0.1	0.2	0.3	0	0.2	0.2	0.9	0.1	0	0	0.1	0.3	0.3	0.2		0.4	0.3
Ecstasy LTP All adults		1.7	5.8	2.1	2.4		6.9	0.4	3.6	2.4	1.8	2.0	2.7	2.1	2.4	0.7	6.2	2.3	3.4	1.3	0.7	1.9	1.8	2.1	8.6	2.5	0.1	1	3.3
Ecstasy LYP All adults		0.7	1.6	0.3	0.4	1.2	0.5	0.2	0.7	0.2	0	0.6	0.4	1	0.5	0.2	1.4	0.5	1.5	0.4	0.2	0.5	0.4	0.1	1.4	0.4		0.3	0.6
Ecstasy LMP All adults		0.3	0.1	0.1	0.2	0.2	0.1	0	0.3		0	0.3	0	0.3	0.2	0.2	0.4	0.2	0.6	0.2	0.1	0.2	0.1	0	0.5	0.2		0.1	0.3
Cocaine LTP Young adults		3	2.5	8.9	5.0		9.4	1.0	11.1	6.0	6.5	5.3	2.2	0.7	1.8	0.9	7.6	2.8	2.3	2.8	0.7	1.1	2.6	4.6	13.6	3.8		4.2	6.1
Cocaine LYP Young adults	2.0	1.5	1.1	2.5	1.8	1.3	2.8	0.2	3.6	1.9	1.3	2.2	0.3	0.3	0.4		2.4	1.2	1.3	1.2	0.2	0.4	0.6	1.2	4.2	0.9		0.6	1.9
Cocaine LMP Young adults		0.8	0.3	0.6	0.4	0.2	1	0.1	1.7		0.5	1.3	0.1	0.1	0.2			0.5	0.9	0.6	0	0.2	0	0.3	1.9	0.4		0.1	0.8
Amphetamines LTP Young adults		4.4	3.9	10.3	5.4		6.4	0.2	4.6	2.4	2.2	1.2	3.5	2.5	4.0	0.7	5.1	3.1	8.2	1.3	0.1	1.2	4.3	5.7	12.4	5.1	0.4	6.0	5.5
Amphetamines LYP Young adults		2.1	1.4	2	1.9	2.5	0.8	0.1	1.1	0.5	0.1	0.7	0.6	1.1	1.2			0.9	3.9	0.4	0	0.3	1.6	1.5	1.4	1.6		0.8	1.3
Amphetamines LMP Young adults		1.1	0	0.6	0.9	1.3	0	0.1	0.5		0	0.3	0.2		0.5			0.3	1.8	0.2	0	0	0.5	0.2	0.5	0.5		0.3	0.6
Ecstasy LTP Young adults		3.6	9.7	5.8	5.0		11	0.6	5.7	4.5	2.9	3.8	4.4	3.9	5.1	1.4	12	3.3	6.5	2.6	0.9	3.5	3.9	3.7	12.2	4.6	0.1	2.1	5.7
Ecstasy LYP Young adults		1.6	2.5	0.8	1.0	2.3	0.9	0.4	1.4	0.4	0.1	1.0	0.8	1.9	1		3.1	1	3.1	0.9	0.4	0.9	1.1	0.2	2.8	0.5	0.1	0.6	1.3
Ecstasy LMP Young adults		0.7	0.3	0.2	0.3	0.5	0.1	0	0.6		0	0.5	0.1	0.6	0.3			0.5	1	0.4	0.3	0.4	0.2	0	1.1	0.2	0.1	0	0.5

Notes:

Data are from the most recent national surveys available in each country (see General population survey tables, Statistical bulletin 2013).

For each country, the average of the sample prevalences, weighted by sample size, is indicated by the highlighted data point

Sources:

Reitox national reports 2012, taken from population surveys, reports or scientific articles.

Substance	Cocaine LTP All adults	Cocaine LYP All adults	Cocaine LMP All adults	Amphetamines LTP All adults	Amphetamines LYP All adults	Amphetamines LMP All adults	Ecstasy LTP All adults	Ecstasy LYP All adults	Ecstasy LMP All adults	Cocaine LTP Young adults	Cocaine LYP Young adults	Cocaine LMP Young adults	Amphetamines LTP Young adults	Amphetamines LYP Young adults	Amphetamines LMP Young adults	Ecstasy LTP Young adults	Ecstasy LYP Young adults	Ecstasy LMP Young adults
Belgium		0.9									2.0
Bulgaria	1.7	0.7	0.4	2.1	0.9	0.5	1.7	0.7	0.3	3	1.5	0.8	4.4	2.1	1.1	3.6	1.6	0.7
Czech Republic	1.4	0.6	0.1	2.1	0.8	0	5.8	1.6	0.1	2.5	1.1	0.3	3.9	1.4	0	9.7	2.5	0.3
Denmark	4.4	0.9	0.2	6.2	0.7	0.3	2.1	0.3	0.1	8.9	2.5	0.6	10.3	2	0.6	5.8	0.8	0.2
Germany	3.3	0.8	0.3	3.7	0.7	0.3	2.4	0.4	0.2	5.0	1.8	0.4	5.4	1.9	0.9	5.0	1.0	0.3
Estonia		0.7	0.1		1.1	0.5		1.2	0.2		1.3	0.2		2.5	1.3		2.3	0.5
Ireland	6.8	1.5	0.5	4.5	0.4	0.1	6.9	0.5	0.1	9.4	2.8	1	6.4	0.8	0	11	0.9	0.1
Greece	0.7	0.1	0	0.1	0	0	0.4	0.2	0	1.0	0.2	0.1	0.2	0.1	0.1	0.6	0.4	0
Spain	8.8	2.3	1.1	3.3	0.6	0.3	3.6	0.7	0.3	###	3.6	1.7	4.6	1.1	0.5	5.7	1.4	0.6
France	3.7	0.9		1.7	0.2		2.4	0.2		6.0	1.9		2.4	0.5		4.5	0.4
Italy	4.2	0.6	0.2	1.8	0.1	0	1.8	0	0	6.5	1.3	0.5	2.2	0.1	0	2.9	0.1	0
Cyprus	3.0	1.2	0.7	0.7	0.3	0.2	2.0	0.6	0.3	5.3	2.2	1.3	1.2	0.7	0.3	3.8	1.0	0.5
Latvia	1.5	0.2	0.1	2.2	0.3	0.1	2.7	0.4	0	2.2	0.3	0.1	3.5	0.6	0.2	4.4	0.8	0.1
Lithuania	0.5	0.2	0.1	1.6	0.7	0.2	2.1	1	0.3	0.7	0.3	0.1	2.5	1.1		3.9	1.9	0.6
Luxembourg
Hungary	0.9	0.2	0.2	1.8	0.5	0.3	2.4	0.5	0.2	1.8	0.4	0.2	4.0	1.2	0.5	5.1	1	0.3
Malta	0.4	0.3	0.1	0.4	0	0	0.7	0.2	0.2	0.9			0.7			1.4
Netherlands	5.2	1.2	0.5	3.1	0.4	0.2	6.2	1.4	0.4	7.6	2.4		5.1			12	3.1
Austria	2.2	0.9	0.6	2.5	0.5	0.2	2.3	0.5	0.2	2.8	1.2	0.5	3.1	0.9	0.3	3.3	1	0.5
Poland	1.3	0.7	0.5	4.2	1.9	0.9	3.4	1.5	0.6	2.3	1.3	0.9	8.2	3.9	1.8	6.5	3.1	1
Portugal	1.9	0.6	0.3	0.9	0.2	0.1	1.3	0.4	0.2	2.8	1.2	0.6	1.3	0.4	0.2	2.6	0.9	0.4
Romania	0.3	0.1	0	0.1	0	0	0.7	0.2	0.1	0.7	0.2	0	0.1	0	0	0.9	0.4	0.3
Slovenia
Slovakia	0.6	0.2	0.1	0.5	0.1	0	1.9	0.5	0.2	1.1	0.4	0.2	1.2	0.3	0	3.5	0.9	0.4
Finland	1.7	0.2	0	2.3	0.8	0.1	1.8	0.4	0.1	2.6	0.6	0	4.3	1.6	0.5	3.9	1.1	0.2
Sweden	3.3	0.5	0.1	5	0.8	0.3	2.1	0.1	0	4.6	1.2	0.3	5.7	1.5	0.2	3.7	0.2	0
UK (England and Wales)	9.6	2.2	1	11.5	0.8	0.3	8.6	1.4	0.5	14	4.2	1.9	12	1.4	0.5	12	2.8	1.1
Croatia	2.3	0.5	0.3	2.6	0.8	0.2	2.5	0.4	0.2	3.8	0.9	0.4	5.1	1.6	0.5	4.6	0.5	0.2
Turkey				0.3			0.1						0.4			0.1	0.1	0.1
Norway	2.5	0.4	0.2	3.8	0.7	0.4	1	0.3	0.1	4.2	0.6	0.1	6.0	0.8	0.3	2.1	0.6	0
EU average	4.2	1	0.5	3.7	0.6	0.3	3.3	0.6	0.3	6.1	1.9	0.8	5.5	1.3	0.6	5.7	1.3	0.5

gpsfig18b

Demonstration	Reference	Type	Y Axis	X axis	Label	Width (%)	Height (px)	Y plotline	Y min,max values	series Markers
	szrfig1	column,column,line	Quantity (kg)\|Number of seizures$3
	szrfig2	column,column,line	Quantity (kg)\|Number of seizures$3
	gpsfig4a	line	%				500		0,30
	gpsfig1	column	%				500		0,25
	gpsfig2	column,column,point	Contiuation rates %\|LTP all adults$3						0,
	gpsfig18a	distribution	Estimated prevalence (%)						0
	gpsfig18b	distribution	Estimated prevalence (%)						0
	gpsfig20	column	%				600		0,20
	dlofig2	stackedBar	%				600
	dlofig3	line	Index (2006 = 100)			68
	dlofig3$	pie			1 135 701 reports (2011)	30
	dlofig4	line	Index (2006 = 100)			68
	dlofig4$	pie			915 541 reports (2011)	30
	dlofig5	line	Index (2006 = 100)			68
	dlofig5$	pie			179 418 reports (2011)	30
	drdfig12a	scatter	Ratio between DRD in 2003 and 2000	Number of DRD in 2000				1
	drdfig12b	scatter	Ratio between DRD in 2010/11 and 2003	Number of DRD in 2003				1
	hsrfig2	stackedColumn	Clients in substitution treatment
	dlofig1	line	Index (2006 = 100)						60,180
	drdfig1	column	Country and total number of DRD				600
	drdfig2	column	Proportion of DRD under the age of 25 (%)				600
	drdfig3	line	Mean age in years
	drdfig4	line	Mean age in years
	drdfig5a	line	Index (1990 = 100)
	drdfig5b	line	Index (1996 = 100)
	drdfig6	line	Index (1990 = 100 %)						80,160
	drdfig7a	column	Mortality rate per million
	drdfig7b	column,point	Rate per million
	drdfig8	line	Index (1985 = 100 %)						50,650
	drdfig9a	line	%						0,70
	drdfig9b	line	%
	drdfig9c	line	%
	drdfig10	column	Mean age in years				500
	drdfig11a	line	Index						0,300
	drdfig11b	line	Index
	drdfig11c	line	Index
	drdfig13a	line	Number of cases
	drdfig13b	line	Number of cases
	eyefig1a	line
	eyefig1b	line
	eyefig1c	line							0,
	eyefig1d	line	%			45	800
	eyefig1d$	line	%			45	800
	gpsfig3	column	%				500
	gpsfig4b	line	%
	gpsfig5	column	%
	gpsfig6	column	%
	gpsfig7	column	%
	gpsfig8a	line	%						0,
	gpsfig8b	line	%						0,
	gpsfig9a	column	%
	gpsfig9b	column	%
	gpsfig10	line	%
	gpsfig11	column,column,point	Continuation rates (%)\| LTP All adults$3
	gpsfig12a	line	%						0,
	gpsfig12b	line	%						0,
	gpsfig13	column,column,point	%
	gpsfig14a	line	%						0,
	gpsfig14b	line	%						0,
	gpsfig15	column	%
	gpsfig16	column,column,point	Continuation rates (%)\|LTP All adults$3						0,
	gpsfig17	column	%
	gpsfig21a	line	%						0,
	gpsfig21b	line	%						0,
	gpsfig22	column,column,point	Continuation rates (%)\| LTP All adults$3
	gpsfig23a	line	%
	gpsfig23b	line	%
	gpsfig23c	line	%
	gpsfig23d	line	%						0,
	gpsfig23e	line	%						0,
	hsrfig4	pie			% of prison population in OST	30
	inffig1a	line	New AIDS cases per million population				700		0,
	inffig1b	line	New AIDS cases per million population				700		0,
	inffig2a	line	Cases per million population						0,
	inffig2b	line	Cases per million population						0,
	inffig2c	line	Cases per million population
	inffig2d	line	Cases per million population
	inffig3a	distribution	%						0,	National;Subnational\|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
	inffig3b	distribution	%						0,	National;Subnational\|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
	inffig3c	distribution	%						0,	National;Subnational\|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
	inffig6a	distribution	%						0,	National;Subnational\|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
	inffig6b	distribution	%						0,	National;Subnational\|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
	inffig6c	distribution	%						0,	National;Subnational\|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
	inffig9a	distribution	%						0,	National;Subnational\|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
	inffig9b	distribution	%						0,	National;Subnational\|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)
	pppfig1	line	Index (2005 = 100)
	pppfig2	line	Index (2005 = 100)
	tdifig1a	line	%
	tdifig1b	line
	tdifig2a	pie				30
	tdifig2b	pie				50
	tdifig3a	line	%
	tdifig3b	line
	tdifig7	line	%			60			0,
	tdifig7$	stackedColumn	Numbers			38			0,50000
	hsrfig1b	stackedColumn	%































Distirbuted points with specific markers and colours	inffig6a	distribution	%							National;Subnational\|square;rgba(0,0,0,0.8);triangle;rgba(0,0,255,0.8)

Download spreadsheet version (.xls)

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read more >>

Contact us

EMCDDA
Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00
Fax (351) 218 13 17 11

More contact options >>

Quick links

Page last updated: Wednesday, 08 May 2013